



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

25 April 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	64,344	10,195	3,576	3,569	2,569	1,374	1,078	482	308
New (1st dose)	5,769	119	0	0	472	128	1	126	62
Total (1st)	2,260,639	355,353	138,739	94,598	113,322	76,857	61,710	41,424	11,284
Total (2nd)	104,538	18,499	5,848	3,943	11,137	2,982	4,321	3,992	1,224
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	19,739	1,065	2,103	3,631	2,608	2,452	4,163	4,984	448
New (1st dose)	2,167	533	348	494	713	246	0	345	15
Total (1st)	481,856	83,585	85,561	116,837	110,428	133,272	150,620	176,407	28,786
Total (2nd)	16,722	5,422	5,898	4,576	4,664	3,841	2,933	5,456	3,080

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	2,365,177	197	0.57%	190	5	0	2
	Total		13,529		13,285	143	43	58
AstraZeneca	New	1,312,004	141	0.92%	137	4	0	0
	Total		12,050		11,864	117	31	38
Pfizer	New	1,053,173	56	0.14%	53	1	0	2
	Total		1,479		1,421	26	12	20

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

25 April 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		644 (100)	118,887 (100)	229.30
Sex	Male	323 (50.16)	59,166 (49.77)	228.77
	Female	321 (49.84)	59,721 (50.23)	229.83
Age	80 or above	18 (2.80)	5,225 (4.39)	275.11
	70-79	47 (7.30)	8,621 (7.25)	239.00
	60-69	84 (13.04)	18,280 (15.38)	288.13
	50-59	113 (17.55)	22,022 (18.52)	254.09
	40-49	93 (14.44)	17,577 (14.78)	209.52
	30-39	94 (14.60)	15,994 (13.45)	227.02
	20-29	110 (17.08)	17,719 (14.90)	260.33
	10-19	58 (9.01)	8,326 (7.00)	168.53
0-9	27 (4.19)	5,123 (4.31)	123.49	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		1 (100)	1,813 (100)	1.52	136 (100)
Sex	Male	0 (0.00)	903 (49.81)	1.53	88 (64.71)
	Female	1 (100)	910 (50.19)	1.52	48 (35.29)
Age	80 or above	1 (100)	995 (54.88)	19.04	34 (25.00)
	70-79	0 (0.00)	520 (28.68)	6.03	40 (29.41)
	60-69	0 (0.00)	212 (11.69)	1.16	42 (30.88)
	50-59	0 (0.00)	62 (3.42)	0.28	14 (10.29)
	40-49	0 (0.00)	14 (0.77)	0.08	5 (3.68)
	30-39	0 (0.00)	7 (0.39)	0.04	0 (0.00)
	20-29	0 (0.00)	3 (0.17)	0.02	1 (0.73)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.12.	4.13.	4.14.	4.15.	4.16.	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.
Total	103	101	100	99	111	108	102	99	109	116	125	127	136	136

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)